Vimarsana
Biggest News Aggregation in the World

Page 21 - Cell Line News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cell Line. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cell Line Today - Breaking & Trending Today

Sniffing out cancer with insect olfactory neural circuits - Vimarsana News

Sniffing out cancer with insect olfactory neural circuits

A fascinating new preprint reports the results of examining the VOC composition from individual cell cultures derived from human oral cancers, using an experimental setup employing an insect brain with attached antenna.

The efficacy of honokiol in inhibiting SARS-CoV-2 replication in cell culture - Vimarsana News

The efficacy of honokiol in inhibiting SARS-CoV-2 replication in cell culture

Researchers evaluated the efficacy of honokiol in inhibiting SARS-CoV-2 replication in cell cultures.

ACROBiosystems was titled 2022 CiteAb Awards protein supplier winner, gaining global scientific approval - Vimarsana News

ACROBiosystems was titled 2022 CiteAb Awards protein supplier winner, gaining global scientific approval

Recently, ACROBiosystems won Cite Awards, being titled "the Winner of Protein Supplier to Watch in 2022".

Study may help overcome some obstacles to the development of nanoparticle-based drugs - Vimarsana News

Study may help overcome some obstacles to the development of nanoparticle-based drugs

Using nanoparticles to deliver cancer drugs offers a way to hit tumors with large doses of drugs while avoiding the harmful side effects that often come with chemotherapy.

Polpharma Biologics Announces EMA Acceptance of Marketing Authorization Application for Proposed Bio - Vimarsana News

Polpharma Biologics Announces EMA Acceptance of Marketing Authorization Application for Proposed Bio

AMSTERDAM, Netherlands, July 14, 2022 / B3C newswire / -- Polpharma Biologics, an international biotech company dedicated to the development of biosimilars, announced today that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorization Application (MAA) for biosimilar natalizumab, a pro...